JP2022529529A5 - - Google Patents

Info

Publication number
JP2022529529A5
JP2022529529A5 JP2021563196A JP2021563196A JP2022529529A5 JP 2022529529 A5 JP2022529529 A5 JP 2022529529A5 JP 2021563196 A JP2021563196 A JP 2021563196A JP 2021563196 A JP2021563196 A JP 2021563196A JP 2022529529 A5 JP2022529529 A5 JP 2022529529A5
Authority
JP
Japan
Prior art keywords
composition
seq
tau
liposomes
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529529A (ja
JP7617852B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029477 external-priority patent/WO2020219646A1/en
Publication of JP2022529529A publication Critical patent/JP2022529529A/ja
Publication of JP2022529529A5 publication Critical patent/JP2022529529A5/ja
Application granted granted Critical
Publication of JP7617852B2 publication Critical patent/JP7617852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563196A 2019-04-24 2020-04-23 タウワクチンの異種投与 Active JP7617852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837987P 2019-04-24 2019-04-24
US62/837,987 2019-04-24
PCT/US2020/029477 WO2020219646A1 (en) 2019-04-24 2020-04-23 Heterologous administration of tau vaccines

Publications (3)

Publication Number Publication Date
JP2022529529A JP2022529529A (ja) 2022-06-22
JP2022529529A5 true JP2022529529A5 (cg-RX-API-DMAC7.html) 2023-09-04
JP7617852B2 JP7617852B2 (ja) 2025-01-20

Family

ID=72921263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563196A Active JP7617852B2 (ja) 2019-04-24 2020-04-23 タウワクチンの異種投与

Country Status (18)

Country Link
US (2) US11591377B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965817A4 (cg-RX-API-DMAC7.html)
JP (1) JP7617852B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220005033A (cg-RX-API-DMAC7.html)
CN (1) CN114173812B (cg-RX-API-DMAC7.html)
AU (1) AU2020262899A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021021213A2 (cg-RX-API-DMAC7.html)
CA (1) CA3137884A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192891A1 (cg-RX-API-DMAC7.html)
IL (1) IL287486A (cg-RX-API-DMAC7.html)
JO (1) JOP20210284A1 (cg-RX-API-DMAC7.html)
MA (1) MA55902A (cg-RX-API-DMAC7.html)
MX (1) MX2021012994A (cg-RX-API-DMAC7.html)
PH (1) PH12021552683A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111770RA (cg-RX-API-DMAC7.html)
TW (1) TW202110478A (cg-RX-API-DMAC7.html)
WO (1) WO2020219646A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108168B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
AU2021276616A1 (en) * 2020-05-20 2023-01-05 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4 and uses thereof
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR20240042508A (ko) * 2021-08-12 2024-04-02 얀센 파마슈티칼즈, 인코포레이티드 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜
EP4408864A4 (en) * 2021-09-29 2025-09-03 Janssen Pharmaceuticals Inc METHOD FOR SAFE ADMINISTRATION OF A TAU PHOSPHOPEPTIDE CONJUGATE

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU690092B2 (en) 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AU2001273361A1 (en) 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
KR100994748B1 (ko) 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
MX2011009654A (es) 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CN105939722A (zh) * 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CN111587123A (zh) * 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物

Similar Documents

Publication Publication Date Title
US20250326806A1 (en) Compositions of Phosphorylated Tau Peptides and Uses Thereof
JP2021501147A5 (cg-RX-API-DMAC7.html)
US11591377B2 (en) Heterologous administration of tau vaccines
KR20200143422A (ko) 항-aveta 치료적 백신
US20250152684A1 (en) Anti-Alpha-Synuclein Therapeutic Vaccines
JP2023536497A (ja) 免疫原性化合物
JP2022533422A5 (cg-RX-API-DMAC7.html)
JP2025506472A5 (cg-RX-API-DMAC7.html)
KR20250135293A (ko) 리포좀 구조체
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
HK40105209A (en) Compositions of phosphorylated tau peptides and uses thereof
JP2024538615A5 (cg-RX-API-DMAC7.html)
EA051687B1 (ru) Терапевтические вакцины против альфа-синуклеина
HK40039870B (en) Compositions of phosphorylated tau peptides and uses thereof
HK40039870A (en) Compositions of phosphorylated tau peptides and uses thereof